BECN1 and chondrosarcoma: Loss of Beclin-1 was linked to poorer survival rate in stage III colon cancer [19], esophageal squamous cell carcinoma [12], hepatocellular carcinoma [15], intrahepatic cholangiocarcinoma [22], pancreatic ductal adenocarcinoma [18], chondrosarcoma [23], and several types of lymphoma [24-26].